Evidence map›Paper›PMID 29574587›Full record

ReviewCurrent cardiology reports2018

Can Nuclear Imaging Techniques Predict Patient Outcome and Guide Medical Management in Hereditary Transthyretin Cardiac Amyloidosis?

Vincent Algalarrondo, Eve Piekarski, Ludivine Eliahou, Dominique Le Guludec, Michel S Slama, François Rouzet

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Comparison of 18F-sodium fluoride positron emission tomography imaging and 99mTc-pyrophosphate in cardiac amyloidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022
    Article
  3. Molecular Imaging of Cardiac Amyloidosis.Current cardiology reports · 2019
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Vincent AlgalarrondoCardiology Department, Antoine Béclère Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), UMR-S 1180, University of Paris-Sud, Clamart, France.
Eve PiekarskiNuclear Medicine Department and DHU FIRE, Bichat Claude Bernard Hospital, AP-HP, University Paris VII, Paris, France.
Ludivine EliahouCardiology Department, Antoine Béclère Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), UMR-S 1180, University of Paris-Sud, Clamart, France.
Dominique Le GuludecNuclear Medicine Department and DHU FIRE, Bichat Claude Bernard Hospital, AP-HP, University Paris VII, Paris, France.
Michel S SlamaCardiology Department, Antoine Béclère Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), UMR-S 1180, University of Paris-Sud, Clamart, France.
François RouzetNuclear Medicine Department and DHU FIRE, Bichat Claude Bernard Hospital, AP-HP, University Paris VII, Paris, France. francois.rouzet@aphp.fr.
Université Paris-Sud · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewNuclear imaging recently gained a key role in the diagnosis and prognostic assessment of transthyretin (TTR)-related cardiac amyloidosis. This review aims at summarizing the state-of-the art regarding the implementation of nuclear imaging in the management of hereditary mutated TTR-cardiac amyloidosis (mTTR-CA). RECENT

findingsAlthough cardiac uptake of bone tracers is acknowledged as a specific marker of TTR amyloid cardiac burden, recent studies validated the implementation of bone scan in the flow chart for non-invasive diagnosis and follow-up of CA in multicenter trials. Simultaneously, cardiac denervation evidenced by MIBG scintigraphy proved to be a strong and independent prognostic marker of poor outcome in mTTR-CA. By its unique ability to assess both amyloid burden and cardiac denervation, nuclear imaging may prove useful as part of multimodality imaging tools to trigger treatment initiation and monitoring in patients with mTTR-CA.

Indexed as

AmyloidAmyloid Neuropathies, FamilialCardiomyopathy, HypertrophicHumansMultimodal ImagingPrealbuminPrognosisRadionuclide ImagingRadiopharmaceuticalsTechnetium Tc 99m MedronateAmyloidPrealbuminRadiopharmaceuticalsTechnetium Tc 99m Medronatetransthyretin-related amyloid fibril protein, humanCardiac amyloidosisDiagnosisNuclear imagingPrognosis

Identifiers

PMID29574587
OpenAlexW2791638874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.